• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Central Nervous System Biomarkers Market Trends

    ID: MRFR/HC/7668-HCR
    120 Pages
    Kinjoll Dey
    October 2025

    Central Nervous System Biomarkers Market Research Report Information by Type Procedure (Safety, Efficacy, Validation Biomarker), Application (Drug Discovery & Development, Personalized Medicine), End Use (Diagnostic Labs, Hospitals & Clinics, Research Centers), and Region (North America, Europe, Asia-Pacific, Rest of the World)—Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Central Nervous System Biomarkers Market Infographic

    Purchase Options

    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Summary Table of Contents Segmentation Download PDF

    Market Trends

    Key Emerging Trends in the Central Nervous System Biomarkers Market

    The Central Nervous System Biomarkers market is experiencing dynamic shifts in response to advancements in neurology research and diagnostics. Several factors are influencing market trends, reflecting a growing understanding of neurological disorders and the need for effective diagnostic tools. One of the key drivers is the increasing prevalence of central nervous system disorders, such as Alzheimer's and Parkinson's diseases. As the global population ages, the demand for accurate biomarkers to aid in early detection and monitoring of these conditions is on the rise. The evolution in technology especially in the subjects of genomics and proteomics has provided an opportunity for the inducement of new biomarkers. With these technological advancements it is now possible to detect biomarkers associated with various CNS disorders more effectively and reliably, which has further catalyzed the market growth. The need for biomarkers that would reveal the underlying causes of neurological disorders, disease onset and how it will progress has been promoted by the fact that neurological disorders are mostly characterized by early detection. A growing awareness of the importance of CNS biomarkers in advancing early intervention and individualized treatment approaches is taking place among researchers and healthcare professionals. Research and development activities have already emerged and advanced in academia and the pharmaceutical industry and the market is seeing it through. A spur of partnerships between research institutions and biotechnology companies hastens the discovery and validation of CNS markers hence enhancing the market’s momentum. It has been an age epitomized with era of precision medicine aims to prove the individual patient profile driven personalized treatment principles. Biomarkers that relate to the CNS are central in the identification of particular molecular patterns, and this allows health care provider to administer personalize treatment protocols on individuals with the neurological disorders. As with biomarker development, investment focus has shifted from drugs to CNS biomarkers as awareness is growing in the context of the potential effect of CNS biomarkers on patient outcomes. Due to investment from various organizations both within the public and private sectors, biomarkers for several CNS disorders are being discovered and validated. The importance of CNS biomarkers for enhancing diagnostic accuracy and patient outcomes is recognized by regulatory bodies. Sympathy regulatory arrangements and momentum toward normatarizatsiya encourage trust of participants, aid in development of market CNS Biomarkers. As the understanding of central nervous system disorders deepens and technology continues to advance, the CNS Biomarkers market is poised for significant expansion. Continued collaboration, technological innovation, and a focus on personalized medicine are expected to shape the future landscape of this dynamic market.

    Market Summary

    The Global Central Nervous System Biomarkers Market is projected to grow significantly from 6.5 USD Billion in 2024 to 15.7 USD Billion by 2035.

    Key Market Trends & Highlights

    Central Nervous System Biomarkers Key Trends and Highlights

    • The market is expected to expand at a compound annual growth rate of 8.35 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 15.7 USD Billion, indicating robust growth potential.
    • In 2024, the market is valued at 6.5 USD Billion, reflecting the increasing focus on neurological disorders.
    • Growing adoption of advanced diagnostic technologies due to the rising prevalence of neurological diseases is a major market driver.

    Market Size & Forecast

    2024 Market Size 6.5 (USD Billion)
    2035 Market Size 15.7 (USD Billion)
    CAGR (2025-2035) 8.35%
    Largest Regional Market Share in 2024 latin_america)

    Major Players

    Thermo Fisher Scientific (US), Merck & Co. (US), AbaStarMDx Inc. (US), Abiant, Inc. (US), Avacta Group plc (UK), Diagenic Asa (Norway), Banyan Biomarkers (US), Avid Radiopharmaceuticals Inc. (US), Acumen pharmaceuticals Inc. (US), Siemens AG (Germany), Novartis (Switzerland)

    Market Trends

    The increasing prevalence of neurological disorders is driving the demand for innovative biomarkers that can facilitate early diagnosis and personalized treatment strategies in the Central Nervous System sector.

    National Institute of Neurological Disorders and Stroke (NINDS)

    Central Nervous System Biomarkers Market Market Drivers

    Rising Prevalence of Neurological Disorders

    The increasing incidence of neurological disorders such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis drives the Global Central Nervous System Biomarkers Market Industry. As the global population ages, the prevalence of these conditions is expected to rise significantly. For instance, the World Health Organization indicates that by 2030, the number of individuals aged 60 years and older will reach 1.4 billion, highlighting the urgent need for effective diagnostic tools. This growing demand for biomarkers to aid in early diagnosis and treatment monitoring is projected to contribute to the market's growth, with an estimated value of 6.5 USD Billion in 2024.

    Market Segment Insights

    Regional Insights

    Key Companies in the Central Nervous System Biomarkers Market market include

    Industry Developments

      • InSeptember 2020, Siemens Healthineersannounced a strategic collaboration with Novartis Pharma AG for biomarker development for Multiple Sclerosis.
      • In May 2019, N170 CNS biomarker letter of intent submitted by Roche (Switzerland) was accepted by FDA for autism spectrum disorder.
      • In March 2020, Oculomotor Index was accepted by FDA as a valid biomarker for the diagnosis of autism spectrum disorder, submitted by The Autism Biomarkers Consortium for Clinical Trials (ABC-CT).

    Future Outlook

    Central Nervous System Biomarkers Market Future Outlook

    The Central Nervous System Biomarkers Market is projected to grow at an 8.35% CAGR from 2024 to 2035, driven by advancements in diagnostics, increasing prevalence of neurological disorders, and rising demand for personalized medicine.

    New opportunities lie in:

    • Develop innovative biomarker-based diagnostic tools for early detection of neurodegenerative diseases.
    • Invest in AI-driven analytics platforms to enhance biomarker discovery and validation processes.
    • Forge strategic partnerships with pharmaceutical companies to integrate biomarkers in clinical trials.

    By 2035, the Central Nervous System Biomarkers Market is expected to reach substantial growth, reflecting evolving healthcare needs and technological advancements.

    Market Segmentation

    Report Overview:

    Central Nervous System Biomarkers Market Segmentation

    By type
    • {"Safety Biomarker"=>[]}
    By End User
    • {"Diagnostic Labs"=>[]}
    By Application
    • {"Drug Discovery & Development"=>[]}
    Central Nervous System Biomarkers Market Regional Analysis
    • {"North America"=>[]}

    Report Scope

    Report Attribute/Metric Details
    Market Size 2023 6.01 (USD Billion)
    Market Size 2024 6.50 (USD Billion)
    Market Size 2032 12.24 (USD Billion)
    Compound Annual Growth Rate (CAGR) 8.67 % (2024 - 2032)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2023
    Market Forecast Period 2024 - 2032
    Historical Data 2019 - 2023
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Thermo fisher scientific (US), Merck & Co (US), AbaStarMDx Inc (US), Abiant, Inc (US), Avacta Group Plc (UK), Diagenic Asa (Norway), Banyan Biomarkers (US), Avid Radiopharmaceuticals Inc (US), Acumen pharmaceuticals Inc (US) and others
      Key Market Opportunities   Untapped APAC region have significant opportunity for CNS biomarker market and rising
      Key Market Drivers   New technological advancements and their increased use in the diagnosis of neurodegenerative diseases   Increase in R&D for new CNS biomarkers and successful clinical trials

    Market Highlights

    Author

    Kinjoll Dey
    Research Analyst Level I

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM
    View All

    FAQs

    What is the valuation of the Central Nervous System Biomarkers Market?

    central nervous system biomarkers market is reachinga market value of USD ~12.24 Billion by 2032

    What is the growth rate of the Central Nervous System Biomarkers Market?

    central nervous system biomarkers market is expected to record a CAGR of ~8.67% during the forecast period 2024-2032

    What are the factors driving the Central Nervous System Biomarkers Market?

    The major factors driving the CNS biomarkers market include new technological advancements and their increased use in the diagnosis of neurodegenerative diseases. Moreover, an increase in R&D for new CNS biomarkers and successful clinical trials further contribute to the market growth.

    What is the leading regional Central Nervous System Biomarkers Market?

    North America is expected to dominate the CNS biomarkers market in 2021, owing to the growing geriatric population, the adoption of the latest technologies for CNS disorder treatment, and key industry players across the region.

    Who are the major players in the Central Nervous System Biomarkers Market?

    Some of the key players in the CNS biomarkers market are Thermo Fisher Scientific (US), Merck & Co. (US), AbaStarMDx Inc. (US), Abiant, Inc. (US), Avacta Group plc (UK), Diagenic Asa (Norway), Banyan Biomarkers (US), Avid Radiopharmaceuticals Inc. (US), and Acumen Pharmaceuticals Inc. (US) amongothers.

    1. . EXCECUTIVE SUMMARY
    2. . MARKET INTRODUCTION
    3. . Definition
    4. . Scope of the Study
    5. . Research Objective
    6. . Assumptions
    7. . Limitations
    8. . RESEARCH METHODOLOGY
    9. . Overview
    10. . Data Mining
    11. . Secondary Research
    12. . Primary Research
    13. . Primary Interviews and Information Gathering Process
    14. . Breakdown of Primary Respondents
    15. . Forecasting Application
    16. . Market Size Estimation
    17. . Bottom-Up Approach
    18. . Top-Down Approach
    19. . Data Triangulation
    20. . Validation
    21. . MARKET DYNAMICS
    22. . Overview
    23. . Drivers
    24. . Restraints
    25. . Opportunities
    26. . MARKET FACTOR ANALYSIS
    27. . Porter’s Five Forces Analysis
    28. . Bargaining Power of Suppliers
    29. . Bargaining Power of Buyers
    30. . Threat of New Entrants
    31. . Threat of Substitutes
    32. . Intensity of Rivalry
    33. . Value Chain Analysis
    34. . COVID-19 Impact Analysis
    35. . Market Impact Analysis
    36. . Impact on Supply Chain
    37. . Regional Impact
    38. . Opportunity and Threat Analysis
    39. . GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE
    40. . Overview
    41. . Safety Biomarker
    42. . Efficacy Biomarker
    43. . Validation Biomarker
    44. . Others
    45. . GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION
    46. . Overview
    47. . Drug Discovery & Development
    48. . Personalized Medicine
    49. . Others
    50. . GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USE
    51. . Overview
    52. . Diagnostic Labs
    53. . Clinics/Hospitals
    54. . Research Centers
    55. . GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY REGION
    56. . Overview
    57. . North America
    58. . US
    59. . Canada
    60. . Europe
    61. . Germany
    62. . France
    63. . UK
    64. . Italy
    65. . Spain
    66. . Rest of Europe
    67. . Asia-Pacific
    68. . China
    69. . India
    70. . Japan
    71. . South Korea
    72. . Australia
    73. . Rest of Asia-Pacific
    74. . Rest of the World
    75. . Middle East
    76. . Africa
    77. . Latin America
    78. . COMPANY LANDSCAPE
    79. . Overview
    80. . Competitive Analysis
    81. . Market Share Analysis
    82. . Major Growth Strategy in the Global Central Nervous System Biomarkers Market
    83. . Competitive Benchmarking
    84. . Leading Players in terms of Number of Developments in the Global Central Nervous System Biomarkers Market
    85. . Key Developments and Growth Strategies
    86. . New ProductLaunch/Service Deployment
    87. . Merger &Acquisitions
    88. . Joint Ventures
    89. . Major Players Financial Matrix
    90. . Sales & Operating Income, 2020
    91. . Major Players R&D Expenditure, 2020
    92. . COMPANY PROFILES
    93. . Thermo Fisher Scientific (US)
    94. . Company Overview
    95. . Financial Overview
    96. . Products Offered
    97. . Key Developments
    98. . SWOT Analysis
    99. . Key Strategies
    100. . Merck & Co (US)
    101. . AbaStar MDx Inc (US)
    102. . Abiant, Inc (US)
    103. . Avacta Group Plc (UK)
    104. . Diagenic Asa (Norway)
    105. . Banyan Biomarkers (US)
    106. . Avid Radiopharmaceuticals Inc (US)
    107. . Acumen pharmaceuticals Inc (US)
    108. . Siemens AG (Germany)
    109. . Novartis (Switzerland)
    110. . Others
    111. . APPENDIX
    112. . References
    113. . Related Reports   LIST OF TABLES TABLE 1 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SYNOPSIS, 2018–2027 TABLE 2 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET ESTIMATES & FORECAST, 2018–2027 (USD MILLION) TABLE 3 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION) TABLE 4 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) TABLE 5 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION) TABLE 6 NORTH AMERICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION) TABLE 7 NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) TABLE 8 NORTH AMERICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION) TABLE 9 US: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION) TABLE 10 US CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) TABLE 11 US: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION) TABLE 12 CANADA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION) TABLE 13 CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) TABLE 14 CANADA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION) TABLE 15 EUROPE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION) TABLE 16 EUROPE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) TABLE 17 EUROPE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION) TABLE 18 GERMANY: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION) TABLE 19 GERMANY: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) TABLE 20 GERMANY: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION) TABLE 21 FRANCE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION) TABLE 22 FRANCE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) TABLE 23 FRANCE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION) TABLE 24 ITALY: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION) TABLE 25 ITALY: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) TABLE 26 ITALY: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION) TABLE 27 SPAIN: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION) TABLE 28 SPAIN: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) TABLE 29 SPAIN: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION) TABLE 30 UK: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION) TABLE 31 UK: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) TABLE 32 UK: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION) TABLE 33 REST OF EUROPE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION) TABLE 34 REST OF EUROPE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) TABLE 35 REST OF EUROPE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION) TABLE 36 ASIA-PACIFIC: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION) TABLE 37 ASIA-PACIFIC: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) TABLE 38 ASIA-PACIFIC: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION) TABLE 39 JAPAN: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION) TABLE 40 JAPAN: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) TABLE 41 JAPAN: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION) TABLE 42 CHINA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION) TABLE 43 CHINA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) TABLE 44 CHINA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION) TABLE 45 INDIA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION) TABLE 46 INDIA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) TABLE 47 INDIA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION) TABLE 48 AUSTRALIA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION) TABLE 49 AUSTRALIA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, APPLICATION, 2018–2027 (USD MILLION) TABLE 50 AUSTRALIA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, END USER, 2018–2027 (USD MILLION) TABLE 51 SOUTH KOREA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION) TABLE 52 SOUTH KOREA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, APPLICATION, 2018–2027 (USD MILLION) TABLE 53 SOUTH KOREA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, END USER, 2018–2027 (USD MILLION) TABLE 54 REST OF ASIA-PACIFIC: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION) TABLE 55 REST OF ASIA-PACIFIC: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) TABLE 56 REST OF ASIA-PACIFIC: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION) TABLE 57 REST OF THE WORLD: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION) TABLE 58 REST OF THE WORLD: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, APPLICATION 2018–2027 (USD MILLION) TABLE 59 REST OF THE WORLD: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, END USER, 2018–2027 (USD MILLION) TABLE 60 MIDDLE EAST: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION) TABLE 61 MIDDLE EAST: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, APPLICATION 2018–2027 (USD MILLION) TABLE 62 MIDDLE EAST: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, END USER, 2018–2027 (USD MILLION) TABLE 63 AFRICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION) TABLE 64 AFRICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, APPLICATION 2018–2027 (USD MILLION) TABLE 65 AFRICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, END USER, 2018–2027 (USD MILLION) TABLE 66 LATIN AMERICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION) TABLE 67 LATIN AMERICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, APPLICATION 2018–2027 (USD MILLION) TABLE 68 LATIN AMERICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, END USER, 2018–2027 (USD MILLION) LIST OF FIGURES FIGURE 1 RESEARCH PROCESS FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET FIGURE 4 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY TYPE, 2020 (%) FIGURE 5 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY APPLICATION, 2020 (%) FIGURE 6 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY END USER, 2020 (%) FIGURE 7 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY REGION, 2020 (%) FIGURE 8 NORTH AMERICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY REGION, 2020 (%) FIGURE 9 EUROPE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY REGION, 2020 (%) FIGURE 10 ASIA-PACIFIC: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY REGION, 2020 (%) FIGURE 11 REST OF THE WORLD: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY REGION, 2020 (%) FIGURE 12 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET: COMPANY SHARE ANALYSIS, 2020 (%) FIGURE 13 THERMO FISHER SCIENTIFIC: KEY FINANCIALS FIGURE 14 THERMO FISHER SCIENTIFIC: SEGMENTAL REVENUE FIGURE 15 THERMO FISHER SCIENTIFIC: REGIONAL REVENUE FIGURE 16 MERCK & CO.: KEY FINANCIALS FIGURE 17 MERCK & CO.: SEGMENTAL REVENUE FIGURE 18 MERCK & CO.: REGIONAL REVENUE FIGURE 19 ABASTAR MDX INC.: KEY FINANCIALS FIGURE 20 ABASTAR MDX INC..: SEGMENTAL REVENUE FIGURE 21 ABASTAR MDX INC.: REGIONAL REVENUE FIGURE 22 ABIANT, INC.: KEY FINANCIALS FIGURE 23 ABIANT, INC.: SEGMENTAL REVENUE FIGURE 24 ABIANT, INC.: REGIONAL REVENUE FIGURE 25 AVACTA GROUP PLC: KEY FINANCIALS FIGURE 26 AVACTA GROUP PLC: SEGMENTAL REVENUE FIGURE 27 AVACTA GROUP PLC: REGIONAL REVENUE FIGURE 28 DIAGENIC ASA: KEY FINANCIALS FIGURE 29 DIAGENIC ASA: SEGMENTAL REVENUE FIGURE 30 DIAGENIC ASA: REGIONAL REVENUE FIGURE 31 BANYAN BIOMARKERS: KEY FINANCIALS FIGURE 32 BANYAN BIOMARKERS: SEGMENTAL REVENUE FIGURE 33 BANYAN BIOMARKERS: REGIONAL REVENUE FIGURE 34 AVID RADIOPHARMACEUTICALS INC.: KEY FINANCIALS FIGURE 35 AVID RADIOPHARMACEUTICALS INC.: SEGMENTAL REVENUE FIGURE 36 AVID RADIOPHARMACEUTICALS INC.: REGIONAL REVENUE FIGURE 37 ACUMEN PHARMACEUTICALS INC.: KEY FINANCIALS FIGURE 38 ACUMEN PHARMACEUTICALS INC.: SEGMENTAL REVENUE FIGURE 39 ACUMEN PHARMACEUTICALS INC.: REGIONAL REVENUE FIGURE 40 SIEMENS AG: KEY FINANCIALS FIGURE 41 SIEMENS AG: SEGMENTAL REVENUE FIGURE 42 SIEMENS AG: REGIONAL REVENUE FIGURE 43 NOVARTIS AG: KEY FINANCIALS FIGURE 44 NOVARTIS AG: SEGMENTAL REVENUE FIGURE 45 NOVARTIS AG: REGIONAL REVENUE
    114. List of Tables and Figures
      1. Table FIGURE 1 RESEARCH PROCESS FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET FIGURE 4 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY TYPE, 2020 (%) FIGURE 5 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY APPLICATION, 2020 (%) FIGURE 6 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY END USER, 2020 (%) FIGURE 7 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY REGION, 2020 (%) FIGURE 8 NORTH AMERICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY REGION, 2020 (%) FIGURE 9 EUROPE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY REGION, 2020 (%) FIGURE 10 ASIA-PACIFIC: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY REGION, 2020 (%) FIGURE 11 REST OF THE WORLD: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY REGION, 2020 (%) FIGURE 12 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET: COMPANY SHARE ANALYSIS, 2020 (%) FIGURE 13 THERMO FISHER SCIENTIFIC: KEY FINANCIALS FIGURE 14 THERMO FISHER SCIENTIFIC: SEGMENTAL REVENUE FIGURE 15 THERMO FISHER SCIENTIFIC: REGIONAL REVENUE FIGURE 16 MERCK & CO.: KEY FINANCIALS FIGURE 17 MERCK & CO.: SEGMENTAL REVENUE FIGURE 18 MERCK & CO.: REGIONAL REVENUE FIGURE 19 ABASTAR MDX INC.: KEY FINANCIALS FIGURE 20 ABASTAR MDX INC..: SEGMENTAL REVENUE FIGURE 21 ABASTAR MDX INC.: REGIONAL REVENUE FIGURE 22 ABIANT, INC.: KEY FINANCIALS FIGURE 23 ABIANT, INC.: SEGMENTAL REVENUE FIGURE 24 ABIANT, INC.: REGIONAL REVENUE FIGURE 25 AVACTA GROUP PLC: KEY FINANCIALS FIGURE 26 AVACTA GROUP PLC: SEGMENTAL REVENUE FIGURE 27 AVACTA GROUP PLC: REGIONAL REVENUE FIGURE 28 DIAGENIC ASA: KEY FINANCIALS FIGURE 29 DIAGENIC ASA: SEGMENTAL REVENUE FIGURE 30 DIAGENIC ASA: REGIONAL REVENUE FIGURE 31 BANYAN BIOMARKERS: KEY FINANCIALS FIGURE 32 BANYAN BIOMARKERS: SEGMENTAL REVENUE FIGURE 33 BANYAN BIOMARKERS: REGIONAL REVENUE FIGURE 34 AVID RADIOPHARMACEUTICALS INC.: KEY FINANCIALS FIGURE 35 AVID RADIOPHARMACEUTICALS INC.: SEGMENTAL REVENUE FIGURE 36 AVID RADIOPHARMACEUTICALS INC.: REGIONAL REVENUE FIGURE 37 ACUMEN PHARMACEUTICALS INC.: KEY FINANCIALS FIGURE 38 ACUMEN PHARMACEUTICALS INC.: SEGMENTAL REVENUE FIGURE 39 ACUMEN PHARMACEUTICALS INC.: REGIONAL REVENUE FIGURE 40 SIEMENS AG: KEY FINANCIALS FIGURE 41 SIEMENS AG: SEGMENTAL REVENUE FIGURE 42 SIEMENS AG: REGIONAL REVENUE FIGURE 43 NOVARTIS AG: KEY FINANCIALS FIGURE 44 NOVARTIS AG: SEGMENTAL REVENUE FIGURE 45 NOVARTIS AG: REGIONAL REVENUE
    115. Table FIGURE 1 RESEARCH PROCESS FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET FIGURE 4 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY TYPE, 2020 (%) FIGURE 5 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY APPLICATION, 2020 (%) FIGURE 6 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY END USER, 2020 (%) FIGURE 7 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY REGION, 2020 (%) FIGURE 8 NORTH AMERICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY REGION, 2020 (%) FIGURE 9 EUROPE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY REGION, 2020 (%) FIGURE 10 ASIA-PACIFIC: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY REGION, 2020 (%) FIGURE 11 REST OF THE WORLD: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY REGION, 2020 (%) FIGURE 12 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET: COMPANY SHARE ANALYSIS, 2020 (%) FIGURE 13 THERMO FISHER SCIENTIFIC: KEY FINANCIALS FIGURE 14 THERMO FISHER SCIENTIFIC: SEGMENTAL REVENUE FIGURE 15 THERMO FISHER SCIENTIFIC: REGIONAL REVENUE FIGURE 16 MERCK & CO.: KEY FINANCIALS FIGURE 17 MERCK & CO.: SEGMENTAL REVENUE FIGURE 18 MERCK & CO.: REGIONAL REVENUE FIGURE 19 ABASTAR MDX INC.: KEY FINANCIALS FIGURE 20 ABASTAR MDX INC..: SEGMENTAL REVENUE FIGURE 21 ABASTAR MDX INC.: REGIONAL REVENUE FIGURE 22 ABIANT, INC.: KEY FINANCIALS FIGURE 23 ABIANT, INC.: SEGMENTAL REVENUE FIGURE 24 ABIANT, INC.: REGIONAL REVENUE FIGURE 25 AVACTA GROUP PLC: KEY FINANCIALS FIGURE 26 AVACTA GROUP PLC: SEGMENTAL REVENUE FIGURE 27 AVACTA GROUP PLC: REGIONAL REVENUE FIGURE 28 DIAGENIC ASA: KEY FINANCIALS FIGURE 29 DIAGENIC ASA: SEGMENTAL REVENUE FIGURE 30 DIAGENIC ASA: REGIONAL REVENUE FIGURE 31 BANYAN BIOMARKERS: KEY FINANCIALS FIGURE 32 BANYAN BIOMARKERS: SEGMENTAL REVENUE FIGURE 33 BANYAN BIOMARKERS: REGIONAL REVENUE FIGURE 34 AVID RADIOPHARMACEUTICALS INC.: KEY FINANCIALS FIGURE 35 AVID RADIOPHARMACEUTICALS INC.: SEGMENTAL REVENUE FIGURE 36 AVID RADIOPHARMACEUTICALS INC.: REGIONAL REVENUE FIGURE 37 ACUMEN PHARMACEUTICALS INC.: KEY FINANCIALS FIGURE 38 ACUMEN PHARMACEUTICALS INC.: SEGMENTAL REVENUE FIGURE 39 ACUMEN PHARMACEUTICALS INC.: REGIONAL REVENUE FIGURE 40 SIEMENS AG: KEY FINANCIALS FIGURE 41 SIEMENS AG: SEGMENTAL REVENUE FIGURE 42 SIEMENS AG: REGIONAL REVENUE FIGURE 43 NOVARTIS AG: KEY FINANCIALS FIGURE 44 NOVARTIS AG: SEGMENTAL REVENUE FIGURE 45 NOVARTIS AG: REGIONAL REVENUE

    Central Nervous System Biomarkers Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Related Reports

    Regional Reports
    Country Reports

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials
    Global Magnesium Sulfate Market – Forecast till 2027